

TERIFLUNOMIDE AND DIMETHYLFUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

S. Izquierdo Muñoz¹, A.M. López González¹, M.E. Cárdena García¹, L. Enríquez Olivar¹, E. Queipo García¹, M.T. Sánchez Sánchez¹
¹Hospital Pharmacy, Hospital Clínico Universitario. Valladolid.

Background

The local Pharmacy and Therapeutics Committee (PTC) approved Teriflunomide (TE) and Dimethylfumarate (DMF) for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS), in first line.


Objective

- ✓ To evaluate the use of TE and DMF in RRMS patients in a third level hospital.
- ✓ To assess the treatment adherence to oral drugs against RRMS.

Material and methods


- ✓ Descriptive, observational, retrospective study, from November-2013 to March-2018.
- ✓ Patients who received at least one dose of TE or DMF in our hospital were included.
- ✓ Collected data: sex, age, Expanded Disability Status Scale (EDSS), previous treatments, therapeutic failure, adverse reactions and adherence to medicines.
- ✓ Treatment adherence was calculated by consulting the electronic dispensing register.

Results



- ✓ Median time between start and end of the treatment with parenteral immunomodulatory drug was 3 [0-17.8] years.
- ✓ 40/56 patients had received RRMS parenteral treatments before starting oral RRMS drugs: interferon beta-1b 250 mcg (20.2%), interferon beta-1a 30 mcg (36%), glatiramer acetate (20.2%), interferon beta-1a 22 mcg (8%) and interferon beta-1a 44 mcg (15.6%). The average of previous treatments received per patient was 0.85 ± 0.63 .
- ✓ The average EDSS at the start of oral treatment was 2.08 ± 0.87 .
- ✓ 15/56 patients started oral RRMS drugs in first line.

Reasons to start oral treatments in the first line



12/56 patients stopped treatment with oral RRMS drugs

TE was discontinued for therapeutic failure (6/12) and adverse reaction (2/12).

DMF was discontinued for adverse reactions (4/12).

- ✓ Treatment adherence to oral RRMS drugs was 99.9%.

Conclusion

- ✓ Teriflunomide and Dimethylfumarate are mainly prescribed for the treatment of RRMS after having received parenteral RRMS therapies, according to the protocol approved by the PTC.
- ✓ Adherence was optimal with the new oral medicines.

- ✓ No conflict of interest
- ✓ 4CPS-135
- ✓ ATC code: L03-Immunomodulating agents

